Primary Indication: Ozempic is primarily FDA-approved to improve glycemic control in adults with Type 2 Diabetes Mellitus and to lower the risk of major adverse cardiovascular events (like heart attacks or strokes) in diabetic patients with established heart disease Weight Management Note: While its active ingredient, semaglutide, is widely recognized for weight reduction, Novo Nordisk markets the specific formulation approved strictly for chronic weight management under the brand name Wegovy • Boxed Warning: Semaglutide carries a strict boxed safety warning regarding the risk of Thyroid C-cell tumors. It is completely contraindicated for patients with a personal or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Severe Side Effects: Immediate medical care is necessary if you experience persistent, severe abdominal pain radiating to your back (a sign of acute pancreatitis), sudden changes in vision, or signs of acute kidney injury caused by dehydration from gastrointestinal side effects.
• Storage Instructions: Unopened pre-filled pens must be kept refrigerated at 2°C to 8°C. Never freeze the pen. Once a pen is in use, it can be kept at room temperature (up to 30°C) or in the refrigerator for up to 56 days